Equilibrative ( SLC29A) and concentrative ( SLC28A) nucleoside transporters contribute to proper placental development and mediate uptake of nucleosides/nucleoside-derived drugs. We analyzed placental expression of SLC28A mRNA during gestation. Moreover, we studied in choriocarcinoma-derived BeWo cells whether SLC29A and SLC28A mRNA levels can be modulated by activity of adenylyl cyclase, retinoic acid receptor activation, CpG islands methylation, or histone acetylation, using forskolin, all- trans-retinoic acid, 5-azacytidine, and sodium butyrate/sodium valproate, respectively. We found that expression of SLC28A1, SLC28A2, and SLC28A3 increases during gestation and reveals considerable interindividual variability. SLC28A2 was shown to be a dominant subtype in the first-trimester and term human placenta, while SLC28A1 exhibited negligible expression in the term placenta only. In BeWo cells, we detected mRNA of SLC28A2 and SLC28A3. Levels of the latter were affected by 5-azacytidine and all- trans-retinoic acid, while the former was modulated by sodium valproate (but not sodium butyrate), all- trans-retinoic acid, 5-azacytidine, and forskolin that caused 25-fold increase in SLC28A2 mRNA; we documented by analysis of syncytin-1 that the observed changes in SLC28A expression do not correlate with the morphological differentiation state of BeWo cells. Upregulated SLC28A2 mRNA was reflected in elevated uptake of [3H]-adenosine, high-affinity substrate of concentrative nucleoside transporter 2. Using KT-5720 and inhibitors of phosphodiesterases, we subsequently confirmed importance of cAMP/protein kinase A pathway in SLC28A2 regulation. On the other hand, SLC29A genes exhibited constitutive expression and none of the tested compounds increased SLC28A1 expression to detectable levels. In conclusion, we provide the first evidence that methylation status and activation of retinoic acid receptor affect placental SLC28A2 and SLC28A3 transcription and substrates of concentrative nucleoside transporter 2 might be taken up in higher extent in placentas with overactivated cAMP/protein kinase A pathway and likely in the term placenta.
- Klíčová slova
- cAMP/protein kinase A signaling pathway, concentrative nucleoside transporters, differentiation, epigenetics, gene regulation, human placenta,
- MeSH
- buněčná diferenciace účinky léků fyziologie MeSH
- ekvilibrační proteiny přenášející nukleosidy genetika metabolismus MeSH
- gestační stáří * MeSH
- karbazoly farmakologie MeSH
- lidé MeSH
- membránové transportní proteiny genetika metabolismus MeSH
- messenger RNA metabolismus MeSH
- nádorové buněčné linie MeSH
- placenta účinky léků metabolismus MeSH
- pyrroly farmakologie MeSH
- těhotenství MeSH
- upregulace MeSH
- vývojová regulace genové exprese účinky léků fyziologie MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- cif nucleoside transporter MeSH Prohlížeč
- ekvilibrační proteiny přenášející nukleosidy MeSH
- karbazoly MeSH
- KT 5720 MeSH Prohlížeč
- membránové transportní proteiny MeSH
- messenger RNA MeSH
- pyrroly MeSH
